Adalimumab
Articles · Refrigerated Storage · Lactation Safety Information · New Medicines · Published , updated
398728003
Articles
21st September 2020
Safety in lactation: Drugs for chronic bowel disorders
Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Aminosalicylates for chronic bowel disorders Mesalazine… Adalimumab Azathioprine Balsalazide Beclometasone Budesonide Ciclosporin Gastrointestinal disorders Golimumab Hydrocortisone Infliximab Mercaptopurine Mesalazine Methotrexate Obstetrics and gynaecology Paediatric and neonatal medicine Prednisolone Safety in Lactation Sulfasalazine Teduglutide Ustekinumab Vedolizumab
5th July 2019
RMOC briefing on adalimumab – July 2019
This sixth briefing paper is provided through the RMOC system. It is the July edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resources
16th May 2019
Adalimumab: procurement and reference pricing FAQ
See below for an FAQ document produced through the RMOC system on adalimumab. It includes detail on the procurement process, its outcome and implementation. Adalimumab Biosimilar medicine RMOC medicines optimisation recommendations and resources
18th January 2019
Update on development of biosimilar versions of adalimumab with particular focus on excipients and injection site reactions
An overview of the five versions of adalimumab currently available in the UK. These article focuses on the differences in excipients and in particular the… Acute Care Adalimumab
7th December 2018
RMOC briefing on adalimumab – December
This fifth briefing paper is provided through the RMOC system. It is the December edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resources
15th November 2018
RCN and NHS England briefing on best value biological medicines for specialist nurses
NHS England has worked in partnership with the Royal College of Nursing (RCN) to produce a briefing for specialist nurses on best value biological medicines,… Adalimumab Biosimilar medicine RMOC medicines optimisation recommendations and resources RMOC recommendations and resources
29th October 2018
Adalimumab barriers to uptake: results of national survey
NHS England commissioned NHS Commissioning Support Units as a collaborative to develop and complete a survey of a sample of NHS Trusts to identify the… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resources
29th October 2018
Adalimumab toolkit for commissioners and providers
The Commissioning Support Units have produced an interactive toolkit and associated resources on behalf of (and approved by) the Regional Medicines Optimisation Committees. These resources… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resources
15th October 2018
Adalimumab press release
NHS England has published a press release in relation to the availability of adalimumab which is available here. Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resources
10th October 2018
RMOC briefing on adalimumab – October 2018
This fourth briefing paper is provided through the RMOC system. It forms the October edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesRefrigerated Storage
Humira · AbbVie
AbbVie
Humira
40 mg solution for injection pre-filled syringe, pre-filled pen
In the event of an inadvertent temperature excursion the following data may be used:
A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not used within the 14 -day period
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
For information outside of this excursion, contact AbbVie Ltd directly. Refer to the current BNF for company contact details.
17th April 2019
London MI Service
Amgevita · Amgen Ltd
Amgen Ltd
Amgevita
Solution for injection in pre-filled syringe/pen
In the event of an inadvertent temperature excursion the following data may be used:
The pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The pre-filled syringe or pre-filled pen must be protected from light, and discarded if not used within the 14-day period.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
14 days
29th July 2019
London MI Service
Imraldi · Biogen
Biogen
Imraldi
Solution for injection in a pre-filled pen or syringe
Once exposed to temperatures up to 25°C, the syringe or pen must be used within 28 days or discarded, even if it is returned to the refrigerator.
You should record the date when the syringe or pen is first removed from refrigerator, and the date after which it should be discarded.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
28 days
Yes
1st July 2019
London MI Service
Hyrimoz · Sandoz
Sandoz
Hyrimoz
40mg solution for injection in pre-filled syringe, pre-filled syringe
In the event of an inadvertent temperature excursion the following data may be used:
A single Hyrimoz pre-filled syringe / pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The pre-filled syringe / pre-filled pen must be protected from light, and discarded if not used within the 14-day period.
The manufacturers have stated that they will deal with temperature excursions on a case by case basis to ensure the most up to date information is provided each time. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
1st October 2019
London MI Service
Hulio · Mylan
Mylan
Hulio
40 mg solution for injection pre-filled syringe, pre-filled pen
In the event of an inadvertent temperature excursion the following data may be used:
A single Hulio pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not used within the 14 -day period.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
For information outside of this excursion, contact Mylan directly. Refer to the current BNF for company contact details.
Yes - 14 days from date of excursion
Information not provided by the manufacturer
15th May 2020
London MI Service
Lactation Safety Information
For rheumatoid arthritis
For rheumatoid arthritis
See summary
Moderate amount of published evidence of safety indicates small amounts in breast milk which are likely to be degraded in the infant’s GI tract
Long half-life increases risk of accumulation in breastfed infants
Although large protein molecules may appear in colostrum, risk to preterm infants and neonates is considered to be small and unproven
15th September 2019
New Medicines
Humira · Moderate-to-severe ulcerative colitis (UC) in children unable to have conventional therapies
Information
Humira
Licence extension / variation
AbbVie
AbbVie
Development and Regulatory status
Recommended for approval (Positive opinion)
Recommended for approval (Positive opinion)
Phase III Clinical Trials
Oct 20 · Recommended for EU approval by CHMP - the additional indication is "for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies" [5].
Category
TNF-alfa antagonist
Ulcerative colitis is the most common type of inflammatory disease of the bowel. It has an incidence in the UK of approximately 10 per 100,000 people annually and a prevalence of approximately 240 per 100,000. Ulcerative colitis can develop at any age but peak incidence is between the ages of 15 and 25 years, with a second, smaller peak between 55 and 65 years [1].
Moderate-to-severe ulcerative colitis (UC) in children unable to have conventional therapies
Subcutaneous injection
Trial or other data
Jan 20 · The PIII study NCT02065557, and the open-label long-term PIII trial are ongoing, with estimated primary completion dates of Jun 2020 and May 2023, respectively [4].
Nov 18 · The PIII study NCT02065557 is still recruiting with estimated primary completion date of May 2021. The open-label long-term PIII trial is still enrolling by invitation with estimated primary completion date of May 2023 [3].
Jan 18 · PIII study (NCT02065557) is still recruiting [2].
Nov 15 · Open-label long-term safety and efficacy PIII trial of repeated SC injections of adalimumab in paediatric subjects with ulcerative colitis, who completed M11-290 study starts (M10-870; NCT02632175). The single-group trial is recruiting 93 patients, by invitation only, in the US, Slovakia and Japan [2].
Aug 14 · PIII trial to investigate the efficacy, tolerability, and pharmacokinetics of induction and maintenance therapy with adalimumab in paediatric patients with moderate to severe ulcerative colitis starts (M11-290; NCT02065557). The trial is intended to enrol 225 patients aged 4 to 17 years old from sites around the world including the US and EU (incl. UK). Collection of primary outcome data (clinical remission at 8 and 52 weeks) is due to complete May 21 [2].
Hulio · Rheumatoid arthritis (RA) and other Humira indications
Information
Hulio
Biosimilar
Mylan
Astra-Fujifilm Kyowa Kirin Biologics joint venture
Development and Regulatory status
Licensed but not launched
Launched
Phase III Clinical Trials
Oct 19 · Not currently being marketed; plans for UK launch not available [10].
Oct 18 · Mylan N.V. announced that it has initiated the commercial launch of Hulio across major markets in Europe [9].
Sep 18 · Launch anticipated mid Oct 2018 [8].
Sep 18 · Approved in the EU [7].
Jul 18 · EU positive opinion for treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn´s disease in adults and children, ulcerative colitis and uveitis in adults and children [6].
May 17 · The European Medicines Agency (EMA) accepted the Marketing Authorisation Application (MAA) for FKB327, an adalimumab biosimilar, for review on May 18, 2017 [4].
Category
Tumour necrosis factor (TNF) inhibitor
NICE suggest the benchmark rate for the number of people with RA eligible for and receiving biologic drugs is 86 per 100,000 adults per year
Rheumatoid arthritis (RA) and other Humira indications
Subcutaneous
Trial or other data
Mar 17 · Pharmacokinetic similarity of FKB327 with Humira demonstrated in healthy subjects (n=180). FKB327 was well tolerated with AE´s similar to Humira (EudraCT 2012–005140-23) [3].
Jul 16 · PIII efficacy/safety trial completed in rheumatoid arthritis (NCT0220791), no study results posted [3].
Jul 15 · PIII ARABESC-OLE open extension trial in 480 patients started, to evaluate the safety/efficacy/immunogenicity of adalimumab biosimilar in patients who completed the ARABESC trial [2].
Jan 15 · PIII ARABESC efficacy/safety trial comparing FKB-327 with Humira in 600 patients with rheumatoid arthritis inadequately controlled on methotrexate (EudraCT2014-000109-11; NCT02260791) in US/Canada, Germany, Spain, and other countries [1].
Evidence based evaluations
Idacio, Kromeya · Rheumatoid arthritis (RA) and other Humira indications
Information
Idacio, Kromeya
Biosimilar
Fresenius Kabi Biotech
Fresenius Kabi Biotech
Development and Regulatory status
Launched
Launched
Phase III Clinical Trials
April 2020
Apr 20 · Available in the UK. 2 pack of pre-filled syringes = £633.86, 2 pack of pre-filled pens = £633.86 and 1 pack of solution for injection vials = £316.93 [10,11].
May 19 · Launched in Germany, where it is available as a pre-filled syringe, pre-filled pen and in a vial presentation [9].
Apr 19 · Fresenius announced on 3 April 2019 that it had received European Commission (EC) approval for its adalimumab biosimilar MSB11455 (Idacio) [8].
Apr 19 · Fresenius announced on 3 April 2019 that it had received European Commission (EC) approval for its adalimumab biosimilar MSB11455 (Idacio) [8].
Jan 19 · Proposed licensed indications include treatment of rheumatoid, juvenile idiopathic and psoriatic arthritis, axial spondyloarthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and uveitis [7].
Jan 19 · Recommended for EU approval by CHMP - indicated for rheumatoid arthritis and other indications of Humira [7].
Dec 18 · Fresenius Kabi plans to launch adalimumab biosimilar in Europe in H1 2019 [6].
Dec 17 · Preregistration for psoriasis, PIII for RA [5].
Apr 17 · Merck KgA announces it is divesting its biosimilar business to Fresenius, closing expected H2 2017 [4].
Feb 16 · PIII trial (AURIEL-PsO; NCT02660580) trial of MSB11022 for the treatment of moderate to severe chronic plaque psoriasis initiated in Germany [2].
Category
A biosimilar version of adalimumab, a humanised recombinant monoclonal IgG1 antibody targeting tumour necrosis factor (TNF)-α.
NICE suggest the benchmark rate for the number of people with RA eligible for and receiving biologic drugs is 86 per 100,000 adults per year
Rheumatoid arthritis (RA) and other Humira indications
Subcutaneous injection
Trial or other data
Mar 16 · Merck KGaA announce first patient treated in adalimumab biosimilar candidate study[3].
Feb 16 · AURIEL-PsO (NCT02660580) will compare the safety, efficacy and immunogenicity of MSB 11022 to Humira® and will enrol approximately 406 patients in Germany; enrolment is expected to expand in the US, Bulgaria, Canada, Czech, Estonia, France, Germany, Hungary, Mexico, Poland, Romania, Russia and the UK [2].
Amsparity (EU), Abrilada (US) · Rheumatoid arthritis (RA) and other Humira indications
Information
Amsparity (EU), Abrilada (US)
Biosimilar
Pfizer
Pfizer
Development and Regulatory status
Licensed but not launched
Licensed but not launched
Approved (Licensed)
Aug 20 · Pfizer currently has no plans to launch Amsparity in the EU [14].
Feb 20 · Approved in EU [13].
Jan 20 · Has received approval is US as Abrilada [12].
Dec 19 · Has also been filed in the US [11].
Dec 19 · The proposed indications for Amsparity include rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn´s disease, paediatric Crohn´s disease, ulcerative colitis, uveitis, paediatric uveitis (although not for all strengths). Amsparity will be available as a solution for injection (40mg in a pre-filled syringe and pre-filled pen and, for paediatric use only, 20mg in a pre-filled syringe and 40mg/0.8 ml in a vial) [10].
Dec 19 · Recommended for EU approval by CHMP as Amsparity, for the full indications of the reference product (Humira) [10].
Dec 18 · The application under the brand name Fyzoclad incorporated a subset of indications; a further application including the full spectrum of indications remains under review [9].
Dec 18 · Pfizer have withdrawn their EU Marketing Authorisation Application during the early stages of its assessment by CHMP: the reason given by the company is a change of strategy, although they reserve the right ro re-submit an application in future [8].
Category
A biosimilar version of adalimumab, a humanised recombinant monoclonal IgG1 antibody targeting tumour necrosis factor (TNF)-α.
NICE suggest the benchmark rate for the number of people with RA eligible for and receiving biologic drugs is 86 per 100,000 adults per year
Rheumatoid arthritis (RA) and other Humira indications
Subcutaneous
Trial or other data
Jan 17 · Pfizer announce REFLECTIONS B538-02 trial (NCT02480153) met its primary endpoint by demonstrating that the efficacy of PF-06410293 was equivalent to Humira as measured by ACR20 response rate at week 12 in patients with moderate to severe rheumatoid arthritis [6].
Jan 17 · Estimated completion date for REFLECTIONS B538-02 trial (NCT02480153) is Dec 17 [5].
Oct 14 · PIII study initiated to compare adalimumab biosimilar and adalimumab (Humira®) in combination with methotrexate in moderate to severe RA, who showed inadequate response to the treatment with methotrexate (REFLECTIONS B538-02; EudraCT2014-000352-29). Enrolment is underway in Lithuania and Spain, and is expected to expand to other sites in the EU, Canada, Australia, South America and Asia [3]
Oct 13 · NCT01870986 (REFLECTIONS) is a PI double-blind, randomized, parallel-group, single-dose, 3-arm study comparing pharmacokinetics of PF-06410293 and adalimumab sourced from the US and EU administered to healthy volunteers. The main objective is to demonstrate equivalent pharmacokinetic properties – maximum observed serum concentration (Cmax), area under the curve from time zero to last quantifiable concentration (AUCt) and AUC from time zero extrapolated to infinity (AUC¥) over a period of 43 days. The trial will include 210 healthy adults, aged 18–55 years. It started Jun 13 and is expected to be completed in Feb 2014 [1]
Evidence based evaluations
Yuflyma · Rheumatoid arthritis (RA) and other Humira indications
Information
Yuflyma
Biosimilar
Celltrion
Celltrion
Development and Regulatory status
Pre-registration (Filed)
Pre-registration (Filed)
Phase III Clinical Trials
Apr 20 · Currently pre-registration in the EU. Has been filed using the centralised procedure. The following indications are awaiting approval: RA, juvenile idiopathic arthritis, enthesis-related arthritis, ankylosing spondylitis, axial spondyloarthritis, PsA, psoriasis (adults and children), hidradenitis suppurativa, Crohns disease (adults and children), ulcerative colitis, and uveitis (adults and children) [4].
Apr 19 · Celltrion announced (Mar 19) that it had completed registering patients for its global phase III clinical trial of its candidate adalimumab biosimilar, CT P17 [3].
Aug 18 · Celltrion aims to complete phase 3 clinical trials by 2020 [1].
Aug 18 · CT-P17 is being developed as a high-concentration formulation differentiating it from the other biosimilars in trials or already approved [1].
Category
Tumour necrosis factor (TNF) inhibitor, citrate-free double concentrate (reduced volume) formulation
In the UK the population minimum prevalence of RA was 1.16% in women and 0.44% in men in one study [2].
Rheumatoid arthritis (RA) and other Humira indications
Parenteral
Trial or other data
Apr 20 · Trials used in support of a licence include single-arm PIII (NCT03789292) study in 50 patients with moderate to severe RA recruited in Eastern Europe, double-blind PIII (NCT03789292) study versus Humira, in combination with methotrexate, in 564 adults with moderate to severe RA recruited in Eastern Europe, and PI studies (NCT04295356 and NCT03970824) in healthy subjects recruited in North America and Asia, respectively [4].
adalimumab biosimilar (CHS1420) · Psoriasis and other Humira indications
Information
adalimumab biosimilar (CHS1420)
Biosimilar
Coherus Biosciences
Coherus Biosciences
Development and Regulatory status
Phase III clinical trials
Phase III clinical trials
Phase III clinical trials
Category
A biosimilar version of adalimumab, a humanised recombinant monoclonal IgG1 antibody targeting tumour necrosis factor (TNF)-α.
Psoriasis and other Humira indications
Subcutaneous injection
adalimumab biosimilar (AVT02) · Rheumatoid arthritis (RA), ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s Disease.
Information
adalimumab biosimilar (AVT02)
Biosimilar
Alvotech/Cipla Gulf
Alvotech/Cipla Gulf
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
TNF inhibitor
NICE suggest the benchmark rate for the number of people with RA eligible for and receiving biologic drugs is 86 per 100,000 adults per year
Rheumatoid arthritis (RA), ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s Disease.
Subcutaneous injection
adalimumab biosimilar (M923) · Psoriasis and other Humira indications
Information
adalimumab biosimilar (M923)
Biosimilar
Momenta
Baxalta
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Sep 19 · Momenta Pharmaceuticals Inc announced its financial results for the second quarter of 2019 on 2 August 2019. In this, they reported that they will stop the development of their Humira (adalimumab M923) [5].
Category
A biosimilar version of adalimumab, a humanised recombinant monoclonal IgG1 antibody targeting tumour necrosis factor (TNF)-α.
Psoriasis is a common, chronic relapsing autoimmune-mediated inflammatory skin disorder. The prevalence of psoriasis is estimated to be about 1.3-2.2% in the UK. Plaque psoriasis accounts for 90% of all people with psoriasis, the majority of cases first present before the age of 35 [2].
Psoriasis and other Humira indications
Subcutaneous injection
adalimumab biosimilar (M923) · Rheumatoid arthritis (RA) and other Humira indications
Information
adalimumab biosimilar (M923)
Biosimilar
Momenta
Baxalta
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Sep 19 · Momenta Pharmaceuticals Inc announced its financial results for the second quarter of 2019 on 2 August 2019. In this, they reported that they will stop the development of their Humira (adalimumab M923) [5].
Category
A biosimilar version of adalimumab, a humanised recombinant monoclonal IgG1 antibody targeting tumour necrosis factor (TNF)-α.
NICE suggest the benchmark rate for the number of people with RA eligible for and receiving biologic drugs is 86 per 100,000 adults per year
Rheumatoid arthritis (RA) and other Humira indications
Subcutaneous injection